REMUVA 100 mg PROLONGED-RELEASE TABLETS

Introduction

Package Leaflet: Information for the User

Remuva 100 mg prolonged-release tablets EFG

tapentadol

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Remuva and what is it used for
2. What you need to know before you take Remuva
3. How to take Remuva
4. Possible side effects
5. Storing Remuva
6. Contents of the pack and other information

1. What is Remuva and what is it used for

This medicine is a strong pain reliever that belongs to the class of opioids.

This medicine is used for the treatment of severe chronic pain in adults that can only be adequately managed with an opioid analgesic.

2. What you need to know before you take Remuva

Do not take Remuva

• if you are allergic to tapentadol or any of the other ingredients of this medicine (listed in section 6),
• if you have asthma or if your breathing is slow or shallow to dangerous levels (respiratory depression, hypercapnia),
• if you have intestinal paralysis,
• if you have consumed alcohol, sleeping pills, pain relievers, or other psychotropic medicines (medicines that affect mood and emotions) (see section "Other medicines and Remuva").

Warnings and precautions

Talk to your doctor or pharmacist before you start taking this medicine:

• if your breathing is slow or shallow,
• if you have increased intracranial pressure or altered consciousness up to coma,
• if you have had a head injury or brain tumors,
• if you have liver or kidney disease (see section "How to take Remuva"),
• if you have a disease of the pancreas or bile ducts, including pancreatitis,
• if you are taking medicines called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial agonists of opioid μ receptors (e.g., buprenorphine),
• if you are prone to epilepsy or convulsive seizures, or if you are taking other medicines with a known risk of increasing seizures, as the risk of these seizures may increase,
• if you or a family member have a history of abuse or dependence on alcohol, prescription medicines, or illicit substances ("addiction"),
• if you smoke,
• if you have ever had problems with your mood (depression, anxiety, or personality disorder) or have received psychiatric treatment for other mental illnesses.

This medicine contains tapentadol, which is an opioid medicine. Repeated use of opioid analgesics can reduce their effectiveness (you can get used to them). It can also lead to dependence and abuse, which can result in a potentially fatal overdose. It is essential that you inform your doctor if you think you may have developed dependence on tapentadol. Its use (even at therapeutic doses) can cause physical dependence, which may cause you to suffer from withdrawal effects and a recurrence of your problems if you stop taking this treatment suddenly.

Tapentadol can cause physical and psychological addiction. If you tend to abuse medicines or are dependent on medicines, you should only take these tablets for short periods under strict medical supervision.

Respiratory disorders related to sleep

Tapentadol can cause respiratory disorders related to sleep, such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.

Other medicines and Remuva

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

• The risk of side effects increases if you are taking medicines that can cause seizures (attacks), such as certain antidepressants or antipsychotics. The risk of seizures increases if you take tapentadol simultaneously with these medicines. Your doctor will tell you if this medicine is suitable for you.
• Taking tapentadol with sedative medicines such as benzodiazepines or related medicines (certain sleeping pills or tranquilizers, e.g., barbiturates) or pain relievers like opioids, morphine, and codeine (also as a cough medicine), antipsychotics, antihistamines H1, alcohol increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be potentially fatal. Due to this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor prescribes tapentadol with sedative medicines, you should limit the dose and duration of concomitant treatment.
• The concomitant use of opioids and drugs used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and can be potentially fatal.Inform your doctor if you are taking gabapentin or pregabalin or anyother sedative medicine and follow your doctor's dosage recommendation to the letter. It may be helpful to inform friends or family members so they are aware of the signs and symptoms mentioned above. Contact your doctor when you experience these symptoms.

• If you are taking a type of medicine that affects serotonin levels (e.g., certain medicines for treating depression), talk to your doctor before taking this medicine, as there have been cases of "serotonin syndrome". Serotonin syndrome is a rare but potentially fatal disorder. Symptoms include involuntary rhythmic muscle contractions, including muscles that control eye movement, agitation, excessive sweating, tremors, exaggerated reflexes, increased muscle tension, and body temperature above 38°C. Your doctor can provide additional information.
• The concomitant administration of tapentadol with other types of medicines called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial agonists of opioid μ receptors (e.g., buprenorphine) has not been studied. It is possible that Remuva may not have the same efficacy if administered with one of these medicines. Inform your doctor if you are currently being treated with one of these medicines.
• The administration of tapentadol with potent inhibitors or inducers (e.g., rifampicin, phenobarbital, St. John's Wort) of certain enzymes necessary to eliminate tapentadol from your body may affect the efficacy of tapentadol or may cause adverse effects, especially when starting or stopping this other type of medication. Keep your doctor informed about all the medicines you are taking.
• This medicine should not be taken with MAO inhibitors (medicines for treating depression). Inform your doctor if you are taking MAO inhibitors or if you have taken them in the last 14 days.

Taking Remuva with food, drinks, and alcohol

Do not consume alcohol while taking this medicine, as some of its side effects, such as drowsiness, may increase. Taking food does not affect the effect of this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Do not take this medicine:

• if you are pregnant, unless your doctor has told you to do so, if used during prolonged periods during pregnancy, tapentadol may cause withdrawal symptoms in the newborn, which can be life-threatening if not detected and treated by a doctor,
• while breastfeeding, as it may be excreted in breast milk.

Tapentadol is not recommended

• during labor, as it may cause slow or shallow breathing to dangerous levels (respiratory depression) in the newborn.

Driving and using machines

This medicine can cause drowsiness, dizziness, and blurred vision and may affect your reactions. Be especially careful at the start of treatment, after a dose change, and when taking it with alcohol or tranquilizers.

Ask your doctor if you can drive or use machines.

3. How to take Remuva

Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist again.

Your doctor will adjust the dose according to the intensity of your pain and your personal sensitivity to pain. You should usually take the minimum effective dose to relieve the pain.

Adults

The starting dose is usually 50 mg twice a day, approximately every 12 hours.

Daily doses above 500 mg of tapentadol are not recommended.

Your doctor may prescribe a different dose or dosing regimen, more suitable for you if necessary. If you think the effect of these tablets is too strong or too weak, talk to your doctor or pharmacist.

Elderly patients

In elderly patients (over 65 years of age), the dose does not usually need to be adjusted. However, the elimination of tapentadol may be delayed and slower in some patients in this age group. If this applies to you, your doctor may prescribe a different dosing regimen.

Liver and kidney diseases (hepatic and renal insufficiency)

Patients with severe liver problems should not take this medicine. If you have moderate liver problems, your doctor will prescribe a different dosing regimen. In cases of mild liver problems, no dose adjustment is necessary.

Patients with severe kidney problems should not take these tablets. In cases of mild or moderate kidney problems, no dose adjustment is necessary.

Use in children and adolescents

Tapentadol is not indicated in children and adolescents under 18 years of age.

How and when to take Remuva

Tapentadol should be taken orally.

Always take the tablets whole with a sufficient amount of liquid.

Do not chew or crush them, as this could lead to an overdose because the active substance will be released in your body too quickly.

You can take them on an empty stomach (without food) or with meals.

The tablet can be divided into equal doses.

The coating of the tablet may not be completely digested and may therefore appear, apparently unchanged, in the feces. This should not worry you, as the active substance of the tablet will have been absorbed by the body, and what you see is only the empty coating.

Instructions for opening the blister pack

This medicine is packaged in a child-resistant, perforated unit blister pack. The tablets cannot be pressed through the blister pack. Note the following instructions for opening the blister pack:

1. Cut a single dose along the perforation line of the blister pack.

1. This will allow you to access an unsealed area located at the position where the perforation lines cross.

1. Pull the unsealed part to remove the seal from the lid.

How long to take Remuva

Do not take the tablets for longer than your doctor has told you.

If you take more Remuva than you should

After taking very high doses, you may experience some of the following effects:

• very small pupils
• vomiting
• decreased blood pressure
• rapid heartbeat
• altered consciousness, fainting, or deep loss of consciousness (coma)
• seizures
• slow or shallow breathing to dangerous levels or respiratory arrest

If this happens, you should immediately call a doctor.

In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested. It is recommended to take the package and the package leaflet of the medicine to the healthcare professional.

If you forget to take Remuva

If you forget to take a tablet, you will probably feel pain again. Do not take a double dose to make up for forgotten doses, but continue taking the tablets as before.

If you stop taking Remuva

If you stop or discontinue treatment too early, you will probably feel pain again. If you want to stop treatment, consult your doctor before doing so.

Generally, patients do not experience any side effects after stopping treatment, but in rare cases, people who have taken the tablets for a long time may feel unwell if they stop taking them suddenly.

The symptoms may be:

• restlessness, tearful eyes, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils,

• irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, difficulty sleeping, nausea, loss of appetite, vomiting, diarrhea, and increased blood pressure, respiratory rate, or heart rate.

If you experience any of these symptoms after stopping treatment, consult your doctor.

You should not stop taking this medicine abruptly, unless your doctor tells you to do so. If your doctor wants you to stop taking these tablets, he will tell you how to do it, which may involve gradually reducing the dose.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine may cause adverse effects, although not all people suffer from them.

Adverse effects or important symptoms to be aware of and what to do if you are affected by them:

• This medicine may cause allergic reactions. Symptoms may include wheezing, difficulty breathing, swelling of the eyelids, face or lips, skin rash or itching, especially if they affect the whole body.
• Another serious adverse effect is breathing more slowly or more weakly than normal. It occurs mostly in elderly patients or in weakened patients.

If you experience any of these important symptoms, consult your doctor immediately.

Other adverse effects that may occur:

Very common(may affect more than 1 in 10 people):

• nausea, constipation,
• dizziness, drowsiness, headache.

Common(may affect up to 1 in 10 people):

• decreased appetite, anxiety, depression of mood, difficulty sleeping, nervousness, restlessness, attention disorders,
• tremors, muscle spasms,
• flushing,
• difficulty breathing,
• vomiting, diarrhea, indigestion,
• itching, increased sweating, rash,
• feeling of weakness, fatigue, feeling of change in body temperature, dryness of mucous membranes, water retention (edema).

Uncommon(may affect up to 1 in 100 people):

• allergic reaction to medicines (including swelling under the skin, hives, and in severe cases, difficulty breathing, decreased blood pressure, collapse, or shock),
• weight loss,
• disorientation, confusion, excitability (agitation), altered perception, abnormal dreams, euphoric mood, decreased level of consciousness, memory impairment, mental deterioration,
• fainting, sedation, balance disorder, difficulty speaking, numbness, abnormal sensations in the skin (e.g., tingling, pinching)
• abnormal vision,
• accelerated heart rate, decreased heart rate, palpitations, decreased blood pressure,
• abdominal discomfort,
• hives,
• urinary retention, frequent urination,
• sexual dysfunction,
• drug withdrawal syndrome (see "If you stop treatment with Remuva"), feeling of discomfort, irritability.

Rare(may affect up to 1 in 1,000 people):

• drug dependence, altered thinking, epileptic seizures, feeling of being about to faint, altered coordination,
• slow or shallow breathing to dangerous levels (respiratory depression),
• altered gastric emptying,
• feeling of intoxication, feeling of relaxation.

Frequency not known(frequency cannot be estimated from available data):

• delirium.

In general, the possibility of having suicidal thoughts and behaviors increases in patients with chronic pain. Additionally, some medications for treating depression (with an impact on the brain's neurotransmitter system) may increase this risk, especially at the start of treatment. Although tapentadol also affects neurotransmitters, experience in patients has not proven that it increases this risk.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for human use medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Conservation of Remuva

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging and on the blister after CAD. The expiration date is the last day of the month indicated.

This medicine does not require special storage conditions.

Medicines should not be thrown away through drains or into the trash. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.

6. Package contents and additional information

Composition of Remuva

The active ingredient is tapentadol.

Remuva 100 mg prolonged-release tablets:

Each prolonged-release tablet contains tapentadol phosphate equivalent to 100 mg of tapentadol.

The other components are:

Core of the tablet: microcrystalline cellulose (E460), hypromellose (E464), anhydrous colloidal silica (E551), magnesium stearate.

Coating: hypromellose (E464), glycerol (E422), talc (E553b), microcrystalline cellulose (E460), titanium dioxide (E171); red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172).

Appearance of the product and package contents

Remuva 100 mg prolonged-release tablets are yellowish, oblong, biconvex (7 mm x 14 mm) with a break line on both sides.

The tablet can be divided into equal doses.

Remuva 100 mg prolonged-release tablets are packaged in aluminum-PVC/PE/PVDC blisters, with the following package sizes:

20x1, 24x1, 30x1, 50x1, 54x1, 60x1 or 100x1 in child-resistant, perforated unit blisters.

Not all package sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Aristo Pharma GmbH

Wallenroder Straße 8-10

13435 Berlin

Germany

Manufacturer

Develco Pharma GmbH

Grienmatt 27, Farhnau

79650 Schopfheim

Baden-Wuerttemberg

Germany

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Aristo Pharma Iberia, S.L.

C/ Solana, 26

28850, Torrejón de Ardoz

Madrid, Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Germany Tapentadol Aristo retard 100 mg Retardtabletten

Italy Tapentadolo Aristo

Denmark Tapentadol Aristo

Norway Tapentadol Aristo

Sweden Tapentadol Depot Aristo

Spain Remuva 100 mg prolonged-release tablets EFG

Date of the last revision of this prospectus:September 2022

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/